 Celldex reported positive results from the phase 1b study using CDX-0159 for the treatment of patients with Chronic Inducible Urticaria; Complete response rate of 95. Expansion opportunity for CDX-0159 exists in that results from a phase 1 study using this drug to treat patients with Chronic Spontaneous Urticaria are expected end of 2021. 